Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 27;22(9):2227-2235.
doi: 10.1016/j.celrep.2018.02.014.

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

Jonathan D Finn  1 , Amy Rhoden Smith  1 , Mihir C Patel  1 , Lucinda Shaw  1 , Madeleine R Youniss  1 , Jane van Heteren  1 , Tanner Dirstine  1 , Corey Ciullo  1 , Reynald Lescarbeau  1 , Jessica Seitzer  1 , Ruchi R Shah  1 , Aalok Shah  1 , Dandan Ling  1 , Jacqueline Growe  1 , Melissa Pink  1 , Ellen Rohde  1 , Kristy M Wood  1 , William E Salomon  1 , William F Harrington  1 , Christian Dombrowski  1 , Walter R Strapps  1 , Yong Chang  1 , David V Morrissey  2
Affiliations
Free article

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

Jonathan D Finn et al. Cell Rep. .
Free article

Abstract

The development of clinically viable delivery methods presents one of the greatest challenges in the therapeutic application of CRISPR/Cas9 mediated genome editing. Here, we report the development of a lipid nanoparticle (LNP)-mediated delivery system that, with a single administration, enabled significant editing of the mouse transthyretin (Ttr) gene in the liver, with a >97% reduction in serum protein levels that persisted for at least 12 months. These results were achieved with an LNP delivery system that was biodegradable and well tolerated. The LNP delivery system was combined with a sgRNA having a chemical modification pattern that was important for high levels of in vivo activity. The formulation was similarly effective in a rat model. Our work demonstrates that this LNP system can deliver CRISPR/Cas9 components to achieve clinically relevant levels of in vivo genome editing with a concomitant reduction of TTR serum protein, highlighting the potential of this system as an effective genome editing platform.

Keywords: CRISPR; CRISPR/Cas9; Cas9; LNP; TTR; gene therapy; genome editing; lipid nanoparticle; liver delivery; sgRNA.

PubMed Disclaimer